Beneficial impact of spironolactone in diabetic nephropathy.

BACKGROUND Aldosterone has been suggested to play a role in the initiation and progression of diabetic nephropathy. Currently recommended treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers [renin-angiotensin system (RAS) blockade] does not suppress circulating aldosterone sufficiently. We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on albuminuria and blood pressure in diabetic nephropathy. METHODS Twenty Caucasian type 1 diabetic patients with persistent macroalbuminuria despite antihypertensive treatment, including RAS blockade, completed this double-masked, randomized cross-over trial. Patients were treated in random order with spironolactone 25 mg once daily and matched placebo for two months, respectively, on top of usual antihypertensive treatment. After each treatment period albuminuria, 24-hour blood pressure, and glomerular filtration rate (GFR) were determined. RESULTS Spironolactone on top of usual antihypertensive treatment induced a 30% (95% CI 17 to 41) reduction in albuminuria from [geometric mean (95% CI)] 831 (624 to 1106) mg/24-hour on placebo treatment (P < 0.001), and a reduction in fractional albumin clearance of 35% (20 to 46, P < 0.001). Twenty-four-hour blood pressure showed an insignificant reduction of [mean reduction (95% CI)] 8 (-1 to 17)/3 (-0.2 to 7) mm Hg (P < 0.10). There was an insignificant reversible reduction in GFR during treatment with spironolactone. On spironolactone treatment, one patient was excluded due to hyperkalemia (plasma potassium 5.7 mmol/L) and one due to orthostatic dizziness. Otherwise treatment was well tolerated. CONCLUSION Our results suggest that spironolactone treatment on top of recommended antihypertensive treatment reduces blood pressure and may offer additional renoprotection in type 1 diabetic patients with diabetic nephropathy.

[1]  E. Lewis,et al.  Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  M. Nieminen,et al.  Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[3]  H. Parving,et al.  Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate , 2004, Diabetologia.

[4]  S. Ishibashi,et al.  Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. , 2004, Kidney international.

[5]  A. Morris,et al.  Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes , 2004, Diabetologia.

[6]  B. Brenner,et al.  Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy , 2004, Circulation.

[7]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[8]  M. Ravid,et al.  The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[9]  H. Parving,et al.  Impaired autoregulation of glomerular filtration rate in Type 1 (insulin-dependent) diabetic patients with nephropathy , 1984, Diabetologia.

[10]  B. Rippe What is the role of albumin in proteinuric glomerulopathies? , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  A. Sugawara,et al.  Nongenomic vascular action of aldosterone in the glomerular microcirculation. , 2003, Journal of the American Society of Nephrology : JASN.

[12]  H. Parving,et al.  Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. , 2003, Diabetes care.

[13]  E. Blasi,et al.  Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. , 2003, Kidney international.

[14]  H. Parving,et al.  Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. , 2003, Kidney international.

[15]  H. Parving,et al.  Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. , 2003, Journal of the American Society of Nephrology : JASN.

[16]  G. D'Amico,et al.  Pathophysiology of proteinuria. , 2003, Kidney international.

[17]  F. Rossi,et al.  Aldosterone induces contraction of the resistance arteries in man. , 2003, Atherosclerosis.

[18]  Koichi Hayashi,et al.  Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy , 2003, Hypertension.

[19]  H. Parving,et al.  Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  T. Hostetter,et al.  Aldosterone in progressive renal disease. , 2001, Seminars in nephrology.

[21]  G. Becker,et al.  Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. , 2001, The New England journal of medicine.

[22]  M. Epstein,et al.  Aldosterone as a Determinant of Cardiovascular and Renal Dysfunction , 2001, Journal of the Royal Society of Medicine.

[23]  S. Anker,et al.  Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. , 2001, Journal of the American College of Cardiology.

[24]  M Epstein,et al.  Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift , 2001, Journal of hypertension.

[25]  M. Epstein,et al.  Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  H. Parving,et al.  Glomerular permselectivity in early stages of overt diabetic nephropathy. , 2000, Kidney international.

[27]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[28]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[29]  S. Yusuf,et al.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.

[30]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[31]  N. Okada,et al.  Glomerular hypertension as one cause of albuminuria in Type II diabetic patients , 1999, Diabetologia.

[32]  C. Stier,et al.  Downloaded from http://hyper.ahajournals.org / by guest on February 21, 2013Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats , 2022 .

[33]  P. Rossing,et al.  Promotion, prediction and prevention of progression of nephropathy in Type 1 diabetes mellitus , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[34]  P. Rossing Promotion, prediction, and prevention of progression in diabetic nephropathy. , 1998, Danish medical bulletin.

[35]  C Roberts,et al.  Depression as a risk factor for ischaemic heart disease in men: population based case-control study , 1998, BMJ.

[36]  H. Parving,et al.  Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. , 1997, Kidney international.

[37]  T. Hostetter,et al.  Role of aldosterone in the remnant kidney model in the rat. , 1996, The Journal of clinical investigation.

[38]  B. Pitt Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). , 1996, The American journal of cardiology.

[39]  M. Ullian,et al.  Mechanisms of enhanced angiotensin II–stimulated signal transduction in vascular smooth muscle by aldosterone , 1994, Journal of cellular physiology.

[40]  A. Salvetti,et al.  Vasodilation to acetylcholine in primary and secondary forms of human hypertension. , 1993, Hypertension.

[41]  E. Schiffrin,et al.  Effect of aldosterone on vascular angiotensin II receptors in the rat. , 1985, Canadian journal of physiology and pharmacology.

[42]  B. Brenner,et al.  Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. , 1984, The Journal of clinical investigation.

[43]  A. J. Man in 't Veld,et al.  Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. , 1983, Hypertension.

[44]  M. Weber,et al.  Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. , 1982, Life sciences.

[45]  B. Brenner,et al.  Molecular basis of proteinuria of glomerular origin. , 1978, The New England journal of medicine.

[46]  J. Bröchner-Mortensen,et al.  Selection of routine method for determination of glomerular filtration rate in adult patients. , 1976, Scandinavian journal of clinical and laboratory investigation.

[47]  J. Bröchner-Mortensen A simple method for the determination of glomerular filtration rate. , 1972, Scandinavian journal of clinical and laboratory investigation.